Ocugen, Inc. Announces Issuance of U.S. Patent for Treating Retinal Degenerative Diseases Using Gene Therapy
Ocugen, Inc. Announces Issuance of U.S. Patent for Treating Retinal Degenerative Diseases Using Gene Therapy
Issuance of U.S. Patent No. 11,351,225 Further Enhances Ocugen's Gene Therapy Intellectual Property Portfolio
美國專利11,351,225的發佈進一步增強了Ocugen公司的基因治療知識產權組合
MALVERN, Pa., June 13, 2022 (GLOBE NEWSWIRE) -- $Ocugen(OCGN.US)$, a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals, and vaccines, today announced that on June 7, 2022, the United States Patent and Trademark Office ("USPTO") issued U.S. Patent No. 11,351,225, which is directed to methods for preventing or treating an ocular disease or disorder associated with a retinal degenerative disease.
賓夕法尼亞州馬爾文，2022年6月13日(環球通訊社)$Ocugen(OCGN.US)$致力於發現、開發新的基因和細胞療法、生物製品和疫苗並將其商業化的臨牀階段生物製藥公司今天宣佈，2022年6月7日，美國專利商標局(USPTO)頒發了美國專利11,351,225號，該專利針對的是預防或治療與視網膜退行性疾病相關的眼部疾病或紊亂的方法。
U.S. Patent No. 11,351,225 (the "'225 Patent") covers the use of a nuclear hormone receptor gene, such as NR2E3, RORA, NUPR1, and NR2C1, in treating retinal degenerative diseases as well as reducing the risk of developing such diseases. Additional issued claims pertain to using a nuclear hormone receptor gene to treat retinitis pigmentosa, age-related macular degeneration, and inherited retinal degenerative diseases. The '225 Patent contains 18 claims and expires in March 2034.
美國專利第11,351,225號(“‘225專利”)涵蓋了核激素受體基因的使用，例如NR2E3, RORA, NUPR1，及NR2C1在治療視網膜退行性疾病以及降低罹患此類疾病的風險方面。其他發佈的聲明涉及使用核激素受體基因治療視網膜色素變性、老年性黃斑變性和遺傳性視網膜退行性疾病。‘225專利包含18項權利要求，將於2034年3月到期。
"We are pleased to have been granted this new U.S. patent through our exclusive license agreement with The Schepens Eye Research Institute, an affiliate of Harvard Medical School. We believe this patent significantly validates our modifier gene therapy platform developed by Dr. Neena Haider and augments our growing global patent portfolio," commented Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen.
Ocugen公司董事長、首席執行官兼聯合創始人尚卡爾·穆蘇努裏博士評論説：“我們很高興通過與哈佛醫學院附屬機構謝彭斯眼科研究所的獨家許可協議獲得這項新的美國專利。我們相信，這項專利極大地驗證了我們由尼娜·海德爾博士開發的修飾劑基因療法平臺，並擴大了我們日益增長的全球專利組合。”
This newly allowed patent is exclusive to Ocugen and is the latest U.S. patent issued in connection with Ocugen's gene therapy program for treating retinal degenerative diseases.
這項新批准的專利是Ocugen的獨家專利，是與Ocugen治療視網膜退行性疾病的基因治療計劃有關的最新美國專利。
About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals and vaccines that improve health and offer hope for people and global communities. We are making an impact through courageous innovation, taking science in new directions in service of patients. Our breakthrough modifier gene therapy platform has the potential to treat multiple diseases with one drug and we are advancing research in other therapeutic areas to offer new options for people with unmet medical needs. Discover more at and follow us on Twitter and LinkedIn.
歐庫根公司簡介
Ocugen，Inc.是一家生物技術公司，專注於發現、開發和商業化新的基因和細胞療法、生物製品和疫苗，這些療法可以改善健康，為人們和全球社區帶來希望。我們正在通過大膽的創新產生影響，將科學帶入為患者服務的新方向。我們突破性的修飾劑基因治療平臺具有用一種藥物治療多種疾病的潛力，我們正在推進其他治療領域的研究，為沒有得到滿足的醫療需求的人提供新的選擇。在Twitter和LinkedIn上了解更多並關注我們。
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission ("SEC"), including the risk factors described in the section entitled "Risk Factors" in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.
關於前瞻性陳述的警示説明
本新聞稿包含1995年《私人證券訴訟改革法》所指的前瞻性陳述，這些陳述會受到風險和不確定性的影響。在某些情況下，我們可能會使用“預測”、“相信”、“潛在”、“建議”、“繼續”、“估計”、“預期”、“預期”、“計劃”、“打算”、“可能”、“將”、“應該”或其他表達未來事件或結果不確定性的詞語來識別這些前瞻性陳述。此類陳述會受到許多重要因素、風險和不確定因素的影響，這些因素、風險和不確定因素可能會導致實際事件或結果與我們目前的預期大不相同。這些以及其他風險和不確定性在我們提交給美國證券交易委員會(“美國證券交易委員會”)的定期報告中有更全面的描述，包括我們在提交給美國證券交易委員會的季度和年度報告中題為“風險因素”的章節中描述的風險因素。我們在本新聞稿中所作的任何前瞻性陳述僅限於本新聞稿發佈之日。除非法律另有要求，否則我們沒有義務在本新聞稿發佈之日之後，因新信息、未來事件或其他原因而更新本新聞稿中包含的前瞻性陳述。
Contact
Tiberend Strategic Advisors, Inc.
Jonathan Nugent / Daniel Kontoh-Boateng (Investors)
jnugent@tiberend.com
dboateng@tiberend.com
聯繫人
Tiberend戰略顧問公司
Jonathan Nugent/Daniel Kontoh-Boateng(投資者)
郵箱：jnugent@tiberend.com
郵箱：dboateng@tiberend.com
Dave Schemelia (Media)
dschemelia@tiberend.com
戴夫·斯皮利亞(Dave Schemelia)(媒體)
郵箱：dschemelia@tiberend.com
譯文內容由第三人軟體翻譯。